Teva Pharma (TEVA) PT Raised to $74 at Maxim Group on Deal for Allergan's Generic Drug Business
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Teva Pharma (TEVA) PT Raised to $74 at Maxim Group on Deal for Allergan's Generic Drug Business
July 27, 2015 6:42 AM EDT
HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement regarding Teva's (NYSE and TASE: TEVA) announcement of its entry into an agreement to acquire Allergan's Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan.
Mylan Executive Chairman Robert J. Coury stated: "We congratulate Teva on their agreement to acquire Allergan's generics business and welcome their continued, and potentially enhanced, commitment to the generics industry. As Teva continues to move forward with their... More
July 27, 2015 4:30 AM EDT
Acquisition Strongly Reinforces Teva's Strategy, Accelerates the
Creation of Its New Business Model and Opens a New Set of Possibilities
for the Company In Generics and Specialty
Opportunity to Further Transform the Global Generics Space through
Best-In-Class Generics Pipeline, R&D Capabilities, Operational Network,
Supply Chain, Global Commercial Deployment and Infrastructure
Robust Generics Platform to Support Future Strategic Investment in
Specialty
Teva Will Be a Top 10 Global Pharmaceutical Company
Enhanced Financial Profile with Strong, Diversified Revenues
... More
